vs
Side-by-side financial comparison of Amylyx Pharmaceuticals, Inc. (AMLX) and PROTHENA CORP PUBLIC LTD CO (PRTA). Click either name above to swap in a different company.
Over the past eight quarters, PROTHENA CORP PUBLIC LTD CO's revenue compounded faster (-35.2% CAGR vs -100.0%).
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
Prothena Corporation plc is a late-stage clinical biotechnology firm focused on developing and commercializing innovative antibody therapies for neurodegenerative disorders, rare diseases and immune-related conditions. Its core pipeline targets unmet medical needs including amyloidosis, Parkinson's and Alzheimer's, serving key markets across North America, Europe and the Asia-Pacific.
AMLX vs PRTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $21.0K |
| Net Profit | $-33.0M | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | — | -99.0% |
| Net Profit YoY | 12.1% | 62.7% |
| EPS (diluted) | $-0.28 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $0 | $21.0K | ||
| Q3 25 | $0 | $2.4M | ||
| Q2 25 | $0 | $4.4M | ||
| Q1 25 | $0 | $2.8M | ||
| Q4 24 | $-665.0K | $2.1M | ||
| Q3 24 | $416.0K | $970.0K | ||
| Q2 24 | $-1.0M | $132.0M | ||
| Q1 24 | $88.6M | $50.0K |
| Q4 25 | $-33.0M | — | ||
| Q3 25 | $-34.4M | $-36.5M | ||
| Q2 25 | $-41.4M | $-125.8M | ||
| Q1 25 | $-35.9M | $-60.2M | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-72.7M | $-59.0M | ||
| Q2 24 | $-72.7M | $66.9M | ||
| Q1 24 | $-118.8M | $-72.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 100.8% | — | ||
| Q1 24 | 93.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1666.3% | ||
| Q2 25 | — | -1914.4% | ||
| Q1 25 | — | -2319.0% | ||
| Q4 24 | 6113.4% | — | ||
| Q3 24 | -18187.7% | -6857.0% | ||
| Q2 24 | 7457.1% | 44.2% | ||
| Q1 24 | -137.8% | -163056.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | -1513.1% | ||
| Q2 25 | — | -2845.4% | ||
| Q1 25 | — | -2128.5% | ||
| Q4 24 | 5646.0% | — | ||
| Q3 24 | -17476.9% | -6082.6% | ||
| Q2 24 | 7106.5% | 50.7% | ||
| Q1 24 | -134.0% | -144478.0% |
| Q4 25 | $-0.28 | — | ||
| Q3 25 | $-0.37 | $-0.68 | ||
| Q2 25 | $-0.46 | $-2.34 | ||
| Q1 25 | $-0.42 | $-1.12 | ||
| Q4 24 | $-0.54 | — | ||
| Q3 24 | $-1.07 | $-1.10 | ||
| Q2 24 | $-1.07 | $1.22 | ||
| Q1 24 | $-1.75 | $-1.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $317.0M | $307.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $305.3M | $280.5M |
| Total Assets | $332.6M | $326.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $317.0M | $307.5M | ||
| Q3 25 | $344.0M | $330.8M | ||
| Q2 25 | $180.8M | $371.4M | ||
| Q1 25 | $204.1M | $417.9M | ||
| Q4 24 | $176.5M | $471.4M | ||
| Q3 24 | $234.4M | $519.3M | ||
| Q2 24 | $309.8M | $564.1M | ||
| Q1 24 | $373.3M | $546.5M |
| Q4 25 | $305.3M | $280.5M | ||
| Q3 25 | $332.0M | $295.0M | ||
| Q2 25 | $167.9M | $324.3M | ||
| Q1 25 | $201.4M | $437.7M | ||
| Q4 24 | $164.8M | $486.9M | ||
| Q3 24 | $196.2M | $534.4M | ||
| Q2 24 | $261.3M | $581.9M | ||
| Q1 24 | $324.4M | $502.4M |
| Q4 25 | $332.6M | $326.8M | ||
| Q3 25 | $362.7M | $352.6M | ||
| Q2 25 | $194.6M | $399.1M | ||
| Q1 25 | $219.7M | $495.3M | ||
| Q4 24 | $193.6M | $547.1M | ||
| Q3 24 | $250.7M | $595.3M | ||
| Q2 24 | $332.2M | $645.6M | ||
| Q1 24 | $417.5M | $623.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-27.9M | $-163.6M |
| Free Cash FlowOCF − Capex | $-28.0M | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-123.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-27.9M | $-163.6M | ||
| Q3 25 | $-30.4M | $-40.6M | ||
| Q2 25 | $-25.2M | $-46.3M | ||
| Q1 25 | $-39.8M | $-53.4M | ||
| Q4 24 | $-59.0M | $-150.1M | ||
| Q3 24 | $-41.6M | $-45.2M | ||
| Q2 24 | $-66.6M | $16.0M | ||
| Q1 24 | $-489.0K | $-73.1M |
| Q4 25 | $-28.0M | — | ||
| Q3 25 | $-30.4M | — | ||
| Q2 25 | $-25.3M | — | ||
| Q1 25 | $-39.8M | — | ||
| Q4 24 | $-59.0M | — | ||
| Q3 24 | $-41.6M | — | ||
| Q2 24 | $-66.7M | — | ||
| Q1 24 | $-556.0K | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 8876.4% | — | ||
| Q3 24 | -9997.4% | — | ||
| Q2 24 | 6517.0% | — | ||
| Q1 24 | -0.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3.0% | — | ||
| Q3 24 | 4.6% | — | ||
| Q2 24 | -8.7% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
